Log In
Print
BCIQ
Print
Print this Print this
 

bapineuzumab (AAB-001)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionHumanized mAb against beta amyloid
Molecular Target Beta amyloid
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD); Treat mild to moderate Alzheimer's disease (AD)
Regulatory Designation

Partner

Pfizer Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today